Company profilePharmaceutical#758 of 1,318 in Pakistan✓ No DRAP alerts

PRIX PHARMACEUTICA

Pharmaceutical company · 11 brands · 16 molecules

Ranked #6 of 40 companies in Blood Conditions

11 registered products 15 pharmaceutical brands 16 distinct molecules 0 DRAP alerts

Company overview

11
registered products
15
pharmaceutical brands
16
distinct molecules
7
therapeutic classes
0
DRAP alerts

PRIX PHARMACEUTICA is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 11 product registrations across 16 distinct molecules. Its portfolio is concentrated in Blood Conditions and Antianemic, Iron Preparations. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by PRIX

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

1
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20261

Top molecules by brand count

Therapeutic classes

Blood Conditions · 4Antianemic, Iron Preparations · 2All Other Therapeutic Products, Antidotes · 1Vitamin A, D & Combinations · 1Gonadotropins And Other Ovulation Stimulants · 1Antiemetics & Antinauseants · 1Gastro · 1

Conditions treated

Anaemia · 3Haematopoiesis · 1Vomiting/Emesis · 1

Price band (DRAP official ceilings)

Registered products priced by source
DVAGO7 products · Rs 196.17 – Rs 9,700
Servaid7 products · Rs 187.8 – Rs 6,740.74
Median across source: Rs 441.6

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SHAIGAN PHARMACEUTICALS (PVT) LTD. holds 139 molecules not in this portfolio
AlbendazoleAmikacinAmlodipineAmlodipine BasylateArtemetherAscorbic Acid
Genix Pharma Private Limited holds 156 molecules not in this portfolio
000 I.UAceclofenacAcyclovirAlbendazoleAlfacalcidolAmikacin
GLOBAL BRANDS DISTRIBUTORS holds 5 molecules not in this portfolio
CeftriaxoneDiloxanideEsomeprazoleLignocaineMetronidazole

Get the full profile for PRIX

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.